Self-reported side effects after vaccination against COVID-19 in Honduras
Abstract
Background: In December 2019, in the community of Wuhan, in Hubei, China, a series of atypical pneumonia cases with severe course was identified and the new disease was called COVID-19. By March 2020, the World Health Organization declared a pandemic. Understanding SARS-CoV2 genomic allowed the scientific community to develop vaccine candidates against COVID-19. Over 41 scientific groups conducted clinical trials to prove vaccines efficiency, efficacy, and safety.
Method: A cross sectional retrospective study performed in Honduras since July 21st, 2021, to December 1st, 2021. This study included the population who received at least one dose of any COVID-19 vaccine. The data were collected using an online survey using Google Forms and a QR code to make it easier for the participants to access the survey and to avoid collecting any personal data from the participants. The symptoms were self-reported. A total of 2108 participants were included in the study through the online survey.
Results: The average age of the participants was 34.61±11.129 years with higher frequency of people between 20-29 years old. In 60.7% of the cases, side effects were reported after the first dose of COVID-19 vaccine or in cases when only one dose was required. Only 1916 received a second dose of COVID-19 vaccine and 38.9% of them presented side effects after that second dose. The most common side effect is pain in the injection site (49.7% and 30.7%). The most common systemic side effects are fever (34.8% and 17.5%), headache (33.5% and 19.1%) and myalgia (32.8% and 17.6%).
Conclusions: The side effects reported by the population after any vaccination against COVID-19 are mainly systemic effects like fever, myalgia and headache, while the most common local side effect is pain in the injection site. The rates of side effects are higher in females, and younger participants after both doses, the differences are statistically significant.
Keywords
Full Text:
PDFReferences
Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265-269. doi:10.1038/s41586-020-2008-3
Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199-1207. doi:10.1056/NEJMoa2001316
Zhou P, Yang X Lou, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273. doi:10.1038/s41586-020-2012-7
Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. doi:10.1016/S0140-6736(20)30251-8
Organización Panamericana de la Salud, Organización Mundial de la Salud. Actualización Epidemiológica.; 2020.
Trilla A. Un mundo, una salud: la epidemia por el nuevo coronavirus COVID-19. Med Clin (Barc). 2020;154(5):175-177. doi:10.1016/j.medcli.2020.05.015
Palacios Cruz M, Santos E, Velázquez Cervantes MA, León Juárez M. COVID-19, una emergencia de salud pública mundial. Rev Clínica Española. 2020;(January). doi:10.1016/j.rce.2020.03.001
Pastrian-Soto G. Bases Genéticas y Moleculares del COVID-19 (SARS-CoV-2). Mecanismos de Patogénesis y de Respuesta Inmune. Int J Odontostomatol. 2020;14(3):331-337. doi:10.4067/s0718-381x2020000300331
Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
Aragón-Nogales R, Vargas-Almanza I, Miranda-Novales MG, Miranda-Novales MG. COVID-19 por SARS-CoV-2: La nueva emergencia de salud. Rev Mex Pediatr. 2020;86(6):213-218. doi:10.35366/91871
Rabaan AA, Al-ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV: a comparative overview. Le Infez Med. 2020;(2):174-184.
Li Y Der, Chi WY, Su JH, Ferrall L, Hung CF, Wu TC. Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci. 2020;27(1):1-23. doi:10.1186/s12929-020-00695-2
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/nejmoa2034577
Galván-Casas C, Català A, Muñoz-Santos C. SARS-CoV-2 Vaccines and the Skin. Actas Dermo-Sifiliográficas (English Ed. 2021;112(9):828-836. doi:10.1016/j.adengl.2021.07.028
WHO. Status of COVID-19 Vaccines within WHO EUL / PQ evaluation process.; 2022.
Castells MC, Phillips EJ. Maintaining Safety with SARS-CoV-2 Vaccines. N Engl J Med. 2021;384(7):643-649. doi:10.1056/nejmra2035343
Syed Alwi SAR, Rafidah E, Zurraini A, Juslina O, Brohi IB, Lukas S. A survey on COVID-19 vaccine acceptance and concern among Malaysians. BMC Public Health. 2021;21(1):1-12. doi:10.1186/s12889-021-11071-6
World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Dashboard.
Menni C, Klaser K, May A, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis. 2021;21(7):939-949. doi:10.1016/S1473-3099(21)00224-3
Azimi M, Dehzad WM, Atiq MA, Bahain B, Asady A. Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan. Infect Drug Resist. 2021;Volume 14:4077-4083. doi:10.2147/IDR.S332354
Andrzejczak-Grządko S, Czudy Z, Donderska M. Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci. 2021;25:4418-4421. doi:10.26355/eurrev_202106_26153
Anderson EJ, Rouphael NG, Widge AT, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020;383(25):2427-2438. doi:10.1056/nejmoa2028436
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/nejmoa2035389
Efrati S, Catalogna M, Abu Hamad R, et al. Safety and humoral responses to BNT162b2 mRNA vaccination of SARS-CoV-2 previously infected and naive populations. Sci Rep. 2021;11(1):1-7. doi:10.1038/s41598-021-96129-6
Solomon Y, Eshete T, Mekasha B, Assefa W. Covid-19 vaccine: Side effects after the first dose of the oxford astrazeneca vaccine among health professionals in low-income country: Ethiopia. J Multidiscip Healthc. 2021;14:2577-2585. doi:10.2147/JMDH.S331140
Pani A, Cento V, Vismara C, et al. Results of the RENAISSANCE Study: REsponse to BNT162b2 COVID-19 vacciNe—short- And long-term Immune responSe evAluatioN in health Care workErs. Mayo Clin Proc. 2021;96(12):2966-2979. doi:10.1016/j.mayocp.2021.08.013
Frenck RW, Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021;385(3):239-250. doi:10.1056/nejmoa2107456
Caminati M, Guarnieri G, Batani V, et al. Covid-19 vaccination in patients with severe asthma on biologic treatment: Safety, tolerability, and impact on disease control. Vaccines. 2021;9(8). doi:10.3390/vaccines9080853
Riad A, Hocková B, Kantorová L, et al. Side effects of mrna-based covid-19 vaccine: Nationwide phase iv study among healthcare workers in Slovakia. Pharmaceuticals. 2021;14(9):1-24. doi:10.3390/ph14090873
Li X, Ostropolets A, Makadia R, et al. Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: Multinational network cohort study. BMJ. 2021;373. doi:10.1136/bmj.n1435
Cai C, Peng Y, Shen E, et al. A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. Mol Ther. 2021;29(9):2794-2805. doi:10.1016/j.ymthe.2021.08.001
Madhi SA, Koen AL, Izu A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV. 2021;8(9):e568-e580. doi:10.1016/S2352-3018(21)00157-0
Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines. 2021;9(8):1-10. doi:10.3390/vaccines9080911
Klimek L, Jutel M, Akdis CA, et al. ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. Allergy Eur J Allergy Clin Immunol. 2021;76(6):1624-1628. doi:10.1111/all.14726
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192. doi:10.1016/S1473-3099(20)30843-4
Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(12):1645-1653. doi:10.1016/S1473-3099(21)00319-4
Adam M, Gameraddin M, Alelyani M, et al. Evaluation of post-vaccination symptoms of two common COVID-19 vaccines used in Abha, Aseer region, Kingdom of Saudi Arabia. Patient Prefer Adherence. 2021;15:1963-1970. doi:10.2147/PPA.S330689
Waldhorn I, Holland R, Goshen-Lago T, et al. Six-month efficacy and toxicity profile of bnt162b2 vaccine in cancer patients with solid tumors. Cancer Discov. 2021;11(10):2430-2435. doi:10.1158/2159-8290.CD-21-1072
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of covid-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7). doi:10.3390/jcm10071428
Boekel L, Kummer LY, van Dam KPJ, et al. Adverse events after first COVID-19 vaccination in patients with autoimmune diseases. Lancet Rheumatol. 2021;3(8):e542-e545. doi:10.1016/S2665-9913(21)00181-8
Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet. 2021;398(10295):121-130. doi:10.1016/S0140-6736(21)01420-3
Takuva S, Takalani A, Garrett N, et al. Thromboembolic Events in the South African Ad26.COV2.S Vaccine Study. N Engl J Med. 2021;385(6):570-571. doi:10.1056/nejmc2107920
Veloza-Romero AJ, Díaz-Corredor DM, Rodríguez-Guevara Camila. Eficacia Y Seguridad De Las Vacunas En Desarrollo Contra La Covid-19. Published online 2020:26-27. www.iets.org.co
Laganà AS, Veronesi G, Ghezzi F, et al. Evaluation of menstrual irregularities after COVID-19 vaccination: Results of the MECOVAC survey. Open Med. 2022;17(1):475-484. doi:10.1515/med-2022-0452
Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021;384(23):2187-2201. doi:10.1056/nejmoa2101544
Pascual-Iglesias A, Canton J, Ortega-Prieto AM, Jimenez-Guardeño JM, Regla-Nava JA. An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens. 2021;10(8):1030. doi:10.3390/pathogens10081030
Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2021;385(12):1078-1090. doi:10.1056/nejmoa2110475
Bogdanov G, Bogdanov I, Kazandjieva J, Tsankov N. Cutaneous adverse effects of the available COVID-19 vaccines. Clin Dermatol. 2021;39(3):523-531. doi:10.1016/j.clindermatol.2021.04.001
Niebel D, Novak N, Wilhelmi J, et al. Cutaneous adverse reactions to covid-19 vaccines: Insights from an immuno-dermatological perspective. Vaccines. 2021;9(9). doi:10.3390/vaccines9090944
Winston J, Munien K. Superficial Thrombophlebitis of the Penis following AstraZeneca ChAdOx1-S Vaccination: A Rare Venous Thromboembolic Complication. Eur J Case Reports Intern Med. Published online 2022:1-2. doi:10.12890/2022_003258
Sampath V, Rabinowitz G, Shah M, et al. Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy Eur J Allergy Clin Immunol. 2021;76(6):1640-1660. doi:10.1111/all.14840
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis. 2021;111(January):219-226. doi:10.1016/j.ijid.2021.08.013
Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021;70(38):1344-1348. doi:10.15585/mmwr.mm7038e2
Worm M, Ring J, Klimek L, et al. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen für das praktische Management. MMW - Fortschritte der Medizin. 2021;163(1):48-51. doi:10.1007/s15006-021-9530-6
Al Ghafri TS, Al Balushi L, Al Balushi Z, et al. Reporting at Least One Adverse Effect Post-COVID-19 Vaccination From Primary Health Care in Muscat. Cureus. 2021;13(8). doi:10.7759/cureus.17055
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021;25(3):1663-1669.
DOI: https://doi.org/10.23954/osj.v7i4.3226
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Open Science Journal (OSJ) is multidisciplinary Open Access journal. We accept scientifically rigorous research, regardless of novelty. OSJ broad scope provides a platform to publish original research in all areas of sciences, including interdisciplinary and replication studies as well as negative results.